**Online Supplementary Material for Understanding Outcomes in Family-Based Treatment for Adolescent Anorexia Nervosa: A Network Approach**

 In this online supplement, we present figures depicting expected influence difference test results for the adolescent anorexia nervosa network (**Supplemental Figure 1**) and the parental self-efficacy/AN bridge network (**Supplemental Figure 2**). We also present a figure depicting the results of the bridge expected influence difference test for determining the most statistically significant bridge pathways in the parental self-efficacy/AN bridge network (**Supplemental Figure 3**).

 Additionally, we present results of additional, supplemental analyses concerning prediction of outcomes from central and bridge symptoms. First, we present results of linear regressions predicting continuous outcomes from central and bridge symptoms (note that categorical outcomes are presented in the main manuscript; **Supplemental Table 1**). We also present results from analyses examining the extent to which a symptom’s expected influence or bridge expected influence was associated with its ability to predict outcomes. This analysis is distinct from the analyses predicted in the main manuscript, which examined the extent to which pretreatment elevations in the most central symptoms predicted outcomes. This analysis was based on the procedures conducted by Elliott et al. (2020). First, we computed zero-order correlations between each symptom or node at pre-treatment and the outcome of interest (early response, end-of-treatment weight restoration, end-of-treatment remission). Correlations among symptoms and outcomes were considered to be the individual prognostic value of a symptom for the outcome. Next, we used linear regressions to examine the associations among symptom’s centrality and its prognostic value. This analysis allowed us to determine if symptoms with the highest expected influence also had higher prognostic value and vice versa. Zero-order correlations for the adolescent AN network symptoms and outcomes are presented in **Supplemental Table 2** and zero-order correlations for the parental self-efficacy/AN bridge network symptoms and outcomes are presented in **Supplemental Table 3**. **Supplemental Table 4** presents results examining the association between expected influence or bridge expected influence and symptom prognostic values. Complementing our logistic regression analyses, we found that expected influence of pretreatment symptoms in the adolescent AN network was significantly associated with early response (**Supplemental Figure 4**), but not end-of-treatment outcomes. We also found that bridge expected influence was not associated with early response and end-of-treatment outcomes; however, similar to our logistic regression findings, there was a trend-level association between bridge expected influence and weight restoration (*p* = .07).

 In this Supplement, we additionally present exploratory analyses in which parental level of income was used as a covariate and moderator of central and bridge symptoms in logistic regression analyses predicting early response and end-of-treatment outcomes (**Supplemental Tables 4 and 5**).

**Supplemental Figure 1**

*Adolescent AN Centrality Difference Test*



*Note.* See Table 2 in the main manuscript for a description of nodes.

**Supplemental Figure 2**

*Parental Self-Efficacy/AN Centrality Difference Test*



*Note.* See Table 2 in the main manuscript for a description of nodes.

**Supplemental Figure 3**

*Parental Self-Efficacy/AN Bridge Pathway Difference Test*



*Note.* See Table 2 in the main manuscript for a description of nodes.

**Supplemental Table 1**

*Ability of Central and Bridge Symptoms to Predict Continuous Outcomes*

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | $β$ (SE) | *t* | Adjusted *R*2 |
| **Adolescent AN Network** |  |  |  |
| Early weight gain (in kg)  |  |  | .006 |
|  Intercept | 2.039 (.270) | 7.560\*\*\* |  |
|  **Pretreatment central symptoms** | **-.037 (.018)** | **-1.986\*** |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.008 (.012) | -.642 |  |
|  Duration of illness | .021 (.273) | .076 |  |
| EOT % EBW |  |  | .051 |
|  Intercept | 96.533 (1.288) | 74.949\*\*\* |  |
|  Pretreatment central symptoms | .101 (.090) | 1.117 |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -2.916 (1.270) | -2.296\* |  |
|  Duration of illness | -.175 (.058) | -3.012\*\* |  |
| EOT EDE Global |  |  | .282 |
|  Intercept | -.070 (.152) | -.463 |  |
|  **Pretreatment central symptoms** | **.089 (.011)** | **7.917\*\*\*** |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .398 (.150) | 2.647\*\* |  |
|  Duration of illness | .008 (.007) | 1.112 |  |
| **Parental Self-Efficacy/AN Bridge Network** |  |  |  |
| Early weight gain (in kg) |  |  | .012 |
|  Intercept | 1.959 (.356) | 5.496\*\*\* |  |
|  Pretreatment *central* symptoms | -.013 (.015) | -.883 |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .174 (.358) | .487 |  |
|  Duration of illness | -.012 (.016) | -.768 |  |
| Early weight gain (in kg) |  |  | .010 |
|  Intercept | 2.106 (.416) | 5.064\*\*\* |  |
|  Pretreatment *bridge* symptoms | -.037 (.035) | -1.034 |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .206 (.362) | .571 |  |
|  Duration of illness | -.014 (.016) | -.873 |  |
| EOT % EBW |  |  | .080 |
|  Intercept | 98.095 (1.828) | 53.671\*\*\* |  |
|  Pretreatment *central* symptoms | .108 (.079) | 1.368 |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -2.345 (1.718) | -1.365 |  |
|  Duration of illness | -.283 (.087) | -3.244\*\* |  |
| EOT % EBW |  |  | .081 |
|  Intercept | 97.107 (2.130) | 45.584\*\*\* |  |
|  Pretreatment *bridge* symptoms | .247 (.176) | 1.405 |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -2.300 (1.711) | -1.344 |  |
|  Duration of illness | -.271 (.088) | -3.904\*\* |  |
| EOT EDE Global |  |  | .190 |
|  Intercept | -.120 (.227) | -.528 |  |
|  **Pretreatment *central* symptoms** | **-.051 (.010)** | **-4.98\*\*\*** |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.230 (.219) | -1.370 |  |
|  Duration of illness | .003 (.011) | .356 |  |
| EOT EDE Global |  |  | .148 |
|  Intercept | .229 (.273) | .840 |  |
|  **Pretreatment *bridge* symptoms** | **-.010 (.002)** | **-4.197\*\*\*** |  |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .348 (.223) | -1.556 |  |
|  Duration of illness | -.001 (.001) | -.004 |  |

*Note.* % EBW = percent expected body weight for age, sex, and height based on current weight; CI = confidence interval; EDE = Eating Disorders Examination; EOT = end-of- treatment; kg = kilograms; OR = odds ratio; SE = standard error.

Adolescent AN network central symptoms were feeling fat, dietary restraint, and desiring weight loss. Parental self-efficacy/AN network central symptoms were dietary restraint, feeling fat, desiring weight loss, discomfort eating in front of others, and fear of weight gain. Parental self-efficacy/AN network bridge symptoms were adolescent discomfort eating in front of others, adolescent dietary restraint, and parental sense of responsibility in renourishing their child with AN.

Outcomes were coded such that higher values represent better outcomes (i.e., EDE global scores were reverse-scored).

\**p <* 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.

**Supplemental Table 2**

*Prognostic Value of Symptoms in the Adolescent AN Network*

|  |  |  |  |
| --- | --- | --- | --- |
| Symptom | Early Response(0 = yes, 1 = no) | EOT Weight Restoration(0 = yes, 1= no) | EOT Full Remission (0 = yes, 1 = no) |
| avoideat | .121 | -.059 | -.023 |
| emptystomach | .044 | -.027 | -.029 |
| foodavoid | -.005 | -.051 | -.087 |
| foodpreoc | -.067 | -.020 | .048 |
| fearloc | .042 | -.020 | -.057 |
| otherseeeat | .073 | -.030 | -.041 |
| eatsecret | .037 | -.012 | -.026 |
| guiltyeat | .026 | -.064 | .022 |
| wtdiss | .048 | .020 | -.068 |
| desirelose | .073 | -.064 | -.030 |
| rxweigh | -.017 | -.045 | -.064 |
| react\_gain | .062 | -.051 | -.050 |
| shapediss | .073 | -.082 | -.172 |
| wtshpreoc | .014 | .005 | .079 |
| wtimpt | .104 | .003 | .003 |
| shimpt | .063 | .058 | -.003 |
| controlimpt | .052 | .001 | -.003 |
| wtgainfear | .068 | -.010 | -.004 |
| feelfat | .085 | .009 | -.068 |
| shapevig | .121 | .038 | -.104 |
| flatstomach | .036 | .007 | -.077 |
| dilax | -.034 | -.103 | .014 |
| obe | -.054 | .003 | -.030 |
| siv | .102 | -.090 | -.043 |
| exercise | .055 | -.057 | -.045 |
| restraint | .124 | .018 | -.082 |
| otherssee | .062 | -.033 | -.112 |

*Note.* Prognostic value was determined by computing zero-order Spearman correlations between each symptom prior to FBT and the outcome of interest. Outcomes were coded such that greater values indicate poorer outcome. See Table 2 in the main manuscript for a description of nodes.

**Supplemental Table 3**

*Prognostic Value of Symptoms in the Parental Self-Efficacy/AN Network*

|  |  |  |  |
| --- | --- | --- | --- |
| Symptom | Early Response(0 = yes, 1 = no) | EOT Weight Restoration(0 = yes, 1= no) | EOT Full Remission (0 = yes, 1 = no) |
| knowledge | -.043 | -.034 | -.022 |
| cause | .006 | -.040 | .032 |
| strategies | -.056 | -.060 | -.031 |
| tough | -.119 | -.025 | -.052 |
| instincts | -.189 | -.074 | -.053 |
| therapy | -.049 | -.188 | -.129 |
| respon | .045 | -.118 | -.065 |
| restraint | .073 | -.150 | -.028 |
| avoideat | .078 | .007 | .125 |
| emptystomach | -.006 | -.095 | .058 |
| foodavoid | -.068 | -.125 | -.020 |
| othersseeeat | -.024 | -.171 | -.046 |
| eatsecret | -.065 | -.073 | -.018 |
| wtdiss | .059 | .034 | .122 |
| desirelose | .056 | -.102 | .022 |
| rxweigh | -.096 | -.039 | .003 |
| shapediss | .001 | -.109 | .032 |
| wtimpt | .049 | -.150 | -.054 |
| shimpt | -.047 | -.165 | -.104 |
| wtgainfear | -.003 | -.109 | -.015 |
| seeself | -.048 | -.089 | .008 |
| feelfat | .019 | -.071 | .011 |
| shapevig | .019 | -.213 | -.083 |
| flatstomach | -.038 | .180 | -.076 |
| dilax | -.011 | -.087 | -.107 |
| obe | -.038 | .010 | -.042 |
| siv | -.028 | -.085 | -.091 |
| exercise | .057 | -.250 | -.176 |
| foodpreoc | -.050 | -.206 | -.108 |
| otherssee | -.070 | -.043 | .030 |
| react\_gain | .057 | -.077 | .034 |
| wtshpreoc | -.012 | -.005 | .068 |

*Note.* EOT = end-of-treatment. Prognostic value was determined by computing zero-order Spearman correlations between each symptom prior to FBT and the outcome of interest. Outcomes were coded such that greater values indicate poorer outcome. See Table 2 in the main manuscript for a description of nodes.

**Supplemental Table 4**

*Association Between Pretreatment Expected Influence and Prognostic Value*

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | $β$ (SE) | *t* | Adjusted *R*2 |
| **Adolescent AN Network** |  |  |  |
|  Early response (0 = yes, 1 = no)  |  |  |  |
|  Pretreatment symptom expected influence | .028 (.008) | 3.346\*\* | .282 |
|  EOT weight restoration (0 = yes, 1 = no) |  |  |  |
|  Pretreatment symptom expected influence | .011 (.008) | 1.427 | .038 |
|  EOT full remission (0 = yes, 1 = no) |  |  |  |
|  Pretreatment symptom expected influence | -.010 (.010) | -.965 | .003 |
| **Parental Self-Efficacy/AN Bridge Network** |  |  |  |
|  Early response (0 = yes, 1 = no) |  |  |  |
|  Pretreatment *bridge* expected influence | .003 (.011) | .257 | .031 |
|  EOT weight restoration (0 = yes, 1 = no) |  |  |  |
|  Pretreatment *bridge* expected influence | -.010 (.012) | -.801 | .011 |
|  EOT full remission (0 = yes, 1 = no) |  |  |  |
|  Pretreatment *bridge* expected influence | -.022 (.012) | -1.862 | .073 |

*Note.* EOT = end-of-treatment; SE = standard error.

Outcomes were coded such that lower values represent better outcomes (i.e., EDE global scores were reverse-scored).

\**p <* 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.

**Supplemental Figure 4**

*Effect of Pretreatment Central Symptoms of Adolescent AN on Early Response Status*



**Supplemental Table 5**

*Inclusion of Income as a Covariate in Logistic Regression Analyses*

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | *B* (SE) | Wald’s *z*-statistic | OR (95% CI) |
| **Adolescent AN Network** |  |  |  |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.044 (.505) | 2.069\* | 2.841 (1.096, 8.064) |
|  **Pretreatment central symptoms** | **.054 (.022)** | **2.434\*** | **1.056 (1.011, 1.104)** |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.266 (.337) | -.789 | .767 (.387, 1.459) |
|  Duration of illness | .011 (.015) | .743 | 1.011 (.983, 1.044) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.120 (.592) | -.202 | .887 (.276, 2.896) |
|  $81,000 to 100,000 USD | -.733 (.517) | -1.418 | .481 (.168, 1.299) |
|  $101,000 to 150,000 USD | -.006 (.507) | -.012 | .994 (.355, 2.648) |
|  >$150,000 USD | -.395 (.451) | -.876 | .673 (.263, 1.576) |
| **EOT remission (0 = yes, 1 = no)** |  |  |  |
|  Intercept | -.269 (.524) | -.513 | .764 (.273, 2.170) |
|  Pretreatment central symptoms | .020 (.025) | .799 | 1.020 (.971, 1.073) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .812 (.399) | 2.395\* | 2.253 (1.160, 4.408) |
|  Duration of illness | .038 (.020) | 1.887 | 1.039 (1.001, 1.084) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .183 (.680) | .269 | 1.200 (.321, 4.801) |
|  $81,000 to 100,000 USD | -.272 (.569) | -.479 | .761 (.245, 2.317) |
|  $101,000 to 150,000 USD | -.318 (.546) | -.583 | .727 (.243, 2.101) |
|  >$150,000 USD | -.298 (.475) | -.626 | .743 (.282, 1.846) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | .238 (.504) | .473 | 1.269 (.476, 3.488) |
|  Pretreatment central symptoms | -.035 (.024) | -1.497 | .965 (.921, 1.011) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .407 (.337) | 1.207 | 1.503 (.776, 2.928) |
|  Duration of illness | .045 (.019) | 2.368\* | 1.046 (1.009, 1.087) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.468 (.603) | -.777 | .626 (.189, 2.048) |
|  $81,000 to 100,000 USD | -.530 (.548) | -.967 | .589 (.197, 1.711) |
|  $101,000 to 150,000 USD | -.326 (.527) | -.620 | .721 (.252, 2.011) |
|  >$150,000 USD | -.838 (.457) | -1.835 | .433 (.171, 1.038) |
| **Parental Self-Efficacy/AN Bridge Network** |  |  |  |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 2.235 (1.147) | 1.949 | 9.350 (1.393, 190.763) |
|  Pretreatment ***central***symptoms | .012 (.021) | .593 | 1.013 (.973, 1.055) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -0.126 (.516) | -.244 | .882 (.306, 2.361) |
|  Duration of illness | .017 (.024) | .701 | 1.017 (.973, 1.071) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -1.853 (1.214) | -1.526 | .157 (.007, 1.322) |
|  $81,000 to 100,000 USD | -2.526 (1.204) | -2.099\* | .080 (.004, .631) |
|  $101,000 to 150,000 USD | -1.222 (1.151) | -1.062 | .294 (.014, 2.080) |
|  >$150,000 USD | -3.120 (2.760) | -1.31 |  |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 2.136 (1.194) | 1.789 | 8.466 (1.120, 182.055) |
|  Pretreatment ***bridge***symptoms | .029 (.050) | .588 | 1.030 (.934, 1.137) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.147 (.524) | -.280 | .864 (.295, 2.349) |
|  Duration of illness | .018 (.024) | .746 | 1.018 (.973, 1.073) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -1.866 (1.214) | -1.536 | .155 (.007, 1.305) |
|  $81,000 to 100,000 USD | -2.517 (1.204) | -2.091\* | .081 (.004, .636) |
|  $101,000 to 150,000 USD | -1.228 (1.150) | -1.068 | .293 (.014, 2.065) |
|  >$150,000 USD | 1.651 (1.081) | -1.528 | .192 (.010, 1.096) |
| **EOT remission (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.559 (1.196) | 1.303 | 4.752 (.611, 102.0) |
|  Pretreatment ***central*** symptoms | -.013 (0.022) | .586 | .987 (.943, 1.032) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .453 (.501) | .905 | 1.573 (.586, 4.253) |
|  Duration of illness | .046 (.029) | 1.562 | 1.047 (.991, 1.114) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -1.965 (1.266) | -1.553 | .140 (.006, 1.321) |
|  $81,000 to 100,000 USD | -2.013 (1.186) | -1.697 | .134 (.006, 1.02) |
|  $101,000 to 150,000 USD | -2.300 (1.151) | -1.997\* | .100 (.004, .694) |
|  >$150,000 USD | -1.915 (1.094) | -1.750 | .147 (.008, .878) |
| **EOT remission (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.628 (1.242) | 1.311 | 5.092 (.585, 115.186) |
|  Pretreatment ***bridge*** symptoms | - .026 (.051) | -.498 | .975 (.880, 1.078) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .440 (.499) | .881 | 1.552 (.581, 4.177) |
|  Duration of illness | .046 (.030) | 1.495 | 1.046 (.989, 1.113) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -1.926 (1.269) | 1.518 | .146 (.006, 1.385) |
|  $81,000 to 100,000 USD | -1.995 (1.186) | -1.682 | .136 (.006, 1.038) |
|  $101,000 to 150,000 USD | -2.272 (1.147) | -1.980 | .103 (.005, .707) |
|  >$150,000 USD | -1.890 (1.091) | -1.732 | .151 (.008, .894) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.535 (1.027) | 1.494 | 4.643 (.705, 44.229) |
|  **Pretreatment *central* symptoms** | **-.058 (.025)** | **-2.315\*** | **.943 (.895, .989)** |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .115 (.518) | .222 | 1.122 (.406, 3.152) |
|  Duration of illness | .085 (.032) | 2.607\*\* | 1.089 (1.026, 1.167) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -2.651 (1.118) | -2.370\* | .071 (.006, .551) |
|  $81,000 to 100,000 USD | -1.646 (.983) | -1.675 | .193 (.022, 1.1812) |
|  $101,000 to 150,000 USD | -2.050 (.951) | -2.154\* | .129 (.015, .723) |
|  >$150,000 USD | -2.258 (.878) | -2.572\* | .105 (.014, .498) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.831 (1.084) | 1.689 | 6.239 (.842, 65.420) |
|  **Pretreatment *bridge* symptoms** | **-.110 (.053)** | **-2.067\*** | **.896 (.804, .992)** |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .061 (.514) | .119 | 1.063 (.387, 2.956) |
|  Duration of illness | .077 (.032) | 2.394\* | 1.080 (1.018, 1.155) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -2.472 (1.110) | -2.227\* | .084 (.008, 0.652) |
|  $81,000 to 100,000 USD | -1.573 (.980) | -1.605 | .207 (.024, 1.266) |
|  $101,000 to 150,000 USD | -1.932 (.937) | -2.062 | .145 (.018, .792) |
|  >$150,000 USD | -2.137 (.862) | -2.749 | .118 (.016, .546) |

*Note.* CI = confidence interval; EOT = end-of-treatment; OR = odds ratio; SE = standard error; USD = United States dollars.

Adolescent AN network central symptoms were feeling fat, dietary restraint, and desiring weight loss. Parental self-efficacy/AN network central symptoms were dietary restraint, feeling fat, desiring weight loss, discomfort eating in front of others, and fear of weight gain. Parental self-efficacy/AN network bridge symptoms were adolescent discomfort eating in front of others, adolescent dietary restraint, and parental sense of responsibility in renourishing their child with AN.

Early response is defined as an adolescent gaining at least 2.4 kilograms by the fourth session of FBT. End-of-treatment remission is defined as an adolescent being at least 95% of expected body weight for height, age, and sex *and* having an EDE Global score within 1 standard deviation of norms at end-of-treatment. End-of treatment weight restoration is defined as an adolescent being at least 95% of expected body weight for height, age, and sex at end-of-treatment.

\**p <* 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.

**Supplemental Table 6**

*Inclusion of Income as a Moderator of Central or Bridge Symptoms in Logistic Regression Analyses*

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | *B* (SE) | Wald’s *z*-statistic | OR (95% CI) |
| **Adolescent AN Network** |  |  |  |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 1.301 (.663) | 1.961\* | 3.672 (1.071, 15.095) |
|  Pretreatment central symptoms | .014 (.060) | .209 | 1.015 (.888, 1.173) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.263 (.338) | -.777 | .769 (.387, 1.468) |
|  Duration of illness | .010 (.016) | .656 | 1.010 (.981, 1.043) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.527 (.865) | -.609 | .590 (.104, 3.292) |
|  $81,000 to 100,000 USD | -1.148 (.780) | -1.471 | .317 (.064, 1.408) |
|  $101,000 to 150,000 USD | -.273 (.735) | -.371 | .761 (.166, 3.108) |
|  >$150,000 USD | -.594 (.667) | -.891 | .552 (.134, 1.920) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .063 (.094) | .667 | 1.065 (.883, 1.288) |
|  $81,000 to 100,000 USD | .065 (.090) | .728 | 1.067 (.892, 1.275) |
|  $101,000 to 150,000 USD | .044 (.087) | .502 | 1.044 (.878, 1.240) |
|  >$150,000 USD | .032 (.076) | .415 | 1.032 (.883, 1.196) |
| **EOT remission (0 = yes, 1 = no)** |  |  |  |
|  Intercept | -.142 (.712) | -.200 | .867 (.217, 3.732) |
|  Pretreatment central symptoms | -.003 (.071) | -.044 | .997 (.868, 1.153) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .858 (.344) | 2.491\* | 2.358 (1.202, 4.660) |
|  Duration of illness | .040 (.021) | 1.911 | 1.041 (1.001, 1.087) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .643 (1.048) | .614 | 1.902 (.257, 17.628) |
|  $81,000 to 100,000 USD | -.599 (.881) | -.680 | .550 (.093, 3.044) |
|  $101,000 to 150,000 USD | .038 (.838) | .044 | 1.038 (.191, 5.331) |
|  >$150,000 USD | -.774 (.730) | -1.061 | .461 (.102, 5.331) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.070 (.104) | -.672 | .932 (.754, 1.142) |
|  $81,000 to 100,000 USD | .050 (.101) | .494 | 1.051 (.862, 1.289) |
|  $101,000 to 150,000 USD | -.063 (.090) | -.694 | .939 (.782, 1.20) |
|  >$150,000 USD | .082 (.081) | 1.012 | 1.085 (.922, 1.272) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | .010 (.691) | .014 | 1.010 (.264, 4.184) |
|  Pretreatment central symptoms | -.006 (.067) | -.089 | .994 (.870, 1.138) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .404 (.337) | 1.194 | 1.498 (.772, 2.926) |
|  Duration of illness | .045 (.019) | 2.381\* | 1.046 (1.009, 1.088) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.159 (.915) | -.174 | .853 (.139, 5.287) |
|  $81,000 to 100,000 USD | -.503 (.856) | -.588 | .605 (.108, 3.202) |
|  $101,000 to 150,000 USD | .237 (.823) | .188 | 1.267 (.242, 6.383) |
|  >$150,000 USD | -.647 (.708) | -.915 | .523 (.121, 2.209) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -.041 (.092) | -.443 | . 960 (.798, 1.150) |
|  $81,000 to 100,000 USD | .002 (.094) | .017 | 1.002 (.831, 1.207) |
|  $101,000 to 150,000 USD | -.082 (.088) | -.926 | .922 (.772, 1.095) |
|  >$150,000 USD | -.023 (.075) | -.304 | .977 (.841, 1.133) |
| **Parental Self-Efficacy/AN Bridge Network** |  |  |  |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 3.503 (2.761) | 1.269 | 33.233 (.934, 1.049E+06) |
|  Pretreatment ***central***symptoms | -.068 (.128) | -.529 | .934 (.616, 1.175) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.146 (.520) | -.280 | .864 (.297, 2.334) |
|  Duration of illness | .028 (.027) | 1.042 | 1.028 (.979, 1.090) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -3.387 (2.925) | -1.158 | .034 (<.001, 2.411) |
|  $81,000 to 100,000 USD | -3.390 (2.863) | -1.184 | .034 (<.001, 1.886) |
|  $101,000 to 150,000 USD | -2.634 (2.809) | -.938 | .072 (<.001, 3.376) |
|  >$150,000 USD | -3.120 (2.760) | -1.131 | .044 (<.001, 1.676) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .090 (.141) | .635 | 1.0937 (.849, 1.678) |
|  $81,000 to 100,000 USD | .027 (.143) | .186 | 1.027 (.792, 1.576) |
|  $101,000 to 150,000 USD | .088 (.139) | .638 | 1.092 (.852, 1.668) |
|  >$150,000 USD | .092 (.131) | .704 | 1.097 (.867, 1.668) |
| **Early response (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 4.376 (3.663) | 1.195 | 79.522 (.533, 6.042E+06) |
|  Pretreatment ***bridge***symptoms | -.179 (.282) | -.637 | .836 (.397, 1.387) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | -.118 (.529) | -.224 | .889 (.300, 2.442) |
|  Duration of illness | .019 (.025) | .752 | 1.019 (.972, 1.075) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -3.629 (3.896) | -.931 | .027 (<.001, .113) |
|  $81,000 to 100,000 USD | -4.768 (3.942) | -1.209 | .008 (<.001, 3.450) |
|  $101,000 to 150,000 USD | -3.851 (3.717) | -1.036 | .021 (<.001, 4.639) |
|  >$150,000 USD | -3.991 (3.656) | -1.092 | .018 (<.001, 3.223) |
|  Moderation of bridge symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .0156 (.311) | .503 | 1.169 (.664, 2.552) |
|  $81,000 to 100,000 USD | .206 (.348) | .593 | 1.229 (.650, 2.815) |
|  $101,000 to 150,000 USD | .258 (.302) | .853 | 1.294 (.750, 2.792) |
|  >$150,000 USD | .218 (.290) | .752 | 1.243 (.738, 2.645) |
| **EOT remission (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 12.463 (12.535) | .994 | 2.588E+05 (1.010, -) |
|  Pretreatment ***bridge*** symptoms | -1.070 (1.058) | -1.011 | .342 (<.001, 1.137) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .544 (.528) | 1.030 | 1.722 (.613, 4.957) |
|  Duration of illness | .050 (.032) | 1.564 | 1.051 (.991, 1.123) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -11.644 (12.640) | -.921 | <.001 (<.001, 8.141) |
|  $81,000 to 100,000 USD | -11.438 (12.599) | -.908 | <.001 (<.001, 5.108) |
|  $101,000 to 150,000 USD | -11.922 (12.548) | -.908 | <.001 (<.001, 2.153) |
|  >$150,000 USD | -13.985 (12.524) | -1.117 | 8.439 (<.001, .229) |
|  Moderation of bridge symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .911 (1.071) | .851 | 2.488 (.696, -) |
|  $81,000 to 100,000 USD | .853 (.1072) | .795 | 2.346 (.660, -) |
|  $101,000 to 150,000 USD | .835 (1.067) | .783 | 2.305 (.666, -) |
|  >$150,000 USD | 1.200 (1.060) | 1.132 | 3.321 (.991, -) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 17.897 (17.529) | 1.021 | 5.922E+07 (6.514, 1.602E+38) |
|  Pretreatment *central* symptoms | -.801 (.748) | -1.070 | .449 (.023, .924) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .164 (.527) | .313 | 1.179 (.420, 3.373) |
|  Duration of illness | .075 (.033) | 2.284\* | 1.078 (1.015, 1.156) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -19.488 (17.566) | -1.109 | <.001 (<.001, .044) |
|  $81,000 to 100,000 USD | -18.855 (17.547) | -1.075 | <.001 (<.001, .077) |
|  $101,000 to 150,000 USD | -18.114 (17.539) | -1.033 | <.001 (<.001, .136) |
|  >$150,000 USD | -18.450 (17.532) | -1.052 | <.001 (<.001, .084) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | .796 (.751) | 1.060 | 2.215 (1.046, 43.657) |
|  $81,000 to 100,000 USD | .832 (.751) | 1.107 | 2.298 (1.076, 45.281) |
|  $101,000 to 150,000 USD | .705 (.752) | .938 | 2.023 (.942, 39.887) |
|  >$150,000 USD | .725 (.750) | .967 | 2.064 (.988, 40.643) |
| **EOT weight restoration (0 = yes, 1 = no)** |  |  |  |
|  Intercept | 13.341 (12.043) | 1.108 | 6.220E+05 (6.067, -) |
|  Pretreatment *bridge* symptoms | -1.129 (.997) | -1.132 | .323 (<.001, .867) |
|  Prior treatment |  |  |  |
|  No (reference group) |  |  |  |
|  Yes | .135 (.529) | .254 | 1.144 (.407, 3.308) |
|  Duration of illness | .082 (.033) | 2.453\* | 1.085 (1.020, 1.164) |
|  Family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | -14.965 (12.100) | -1.237 | <.001 (<.001, .056) |
|  $81,000 to 100,000 USD | -12.317 (12.112) | -1.107 | <.001 (<.001, .877) |
|  $101,000 to 150,000 USD | -12.834 (12.062) | -1.064 | <.001 (<.001, .339) |
|  >$150,000 USD | -14.259 (12.037) | -1.185 | <.001 (<.001, .066) |
|  Moderation of central symptoms and family income |  |  |  |
|  <$50,000 USD (reference group) |  |  |  |
|  $50,000 to 80,000 USD | 1.113 (1.006) | 1.106 | 3.045 (1.068, -) |
|  $81,000 to 100,000 USD | .909 (1.012) | .898 | 2.482 (.836, -) |
|  $101,000 to 150,000 USD | .904 (1.007) | .899 | 2.471 (.862, -) |
|  >$150,000 USD | 1.091 (1.000) | 1.091 | 2.978 (1.091, -) |

*Note.* CI = confidence interval; EOT = end-of-treatment; OR = odds ratio; SE = standard error; USD = United States dollars.

Adolescent AN network central symptoms were feeling fat, dietary restraint, and desiring weight loss. Parental self-efficacy/AN network central symptoms were dietary restraint, feeling fat, desiring weight loss, discomfort eating in front of others, and fear of weight gain. Parental self-efficacy/AN network bridge symptoms were adolescent discomfort eating in front of others, adolescent dietary restraint, and parental sense of responsibility in renourishing their child with AN.

Early response is defined as an adolescent gaining at least 2.4 kilograms by the fourth session of FBT. End-of-treatment remission is defined as an adolescent being at least 95% of expected body weight for height, age, and sex *and* having an EDE Global score within 1 standard deviation of norms at end-of-treatment. End-of treatment weight restoration is defined as an adolescent being at least 95% of expected body weight for height, age, and sex at end-of-treatment.

\**p <* 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.